Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 4/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 8/20 | 0.55 |
| ▸ | TUBB | P07437 | 8/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 8/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 8/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 8/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 8/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924403 | 0.90 | BACE1 (0.53) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL3500724 | 0.88 | ATP4A (0.46) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL240221 | 0.83 | TYMS (0.60) | S1PR4S1PR1S1PR5LMNACYP1A2 | |
| SCHEMBL13699194 | 0.82 | TUBB4A (0.46) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL8083831 | 0.81 | TUBB4A (0.55) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL9295731 | 0.80 | MPL (0.67) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL23776494 | 0.79 | TUBB4A (0.53) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL20055055 | 0.79 | S1PR4 (0.63) | S1PR4S1PR1S1PR5TUBB4ATUBB | |
| SCHEMBL12686275 | 0.78 | PLAU (0.58) | CYP1A2CYP2D6PLAUHTR3EHTR3B | |
| SCHEMBL4779966 | 0.78 | TYMS (0.55) | S1PR4S1PR1S1PR5LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008014221-A2 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| US-5326779-A | Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles | THE ROCKEFELLER UNIVERSITY (US) | 1994-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | S1PR4 2273/4885S1PR1 2184/4885S1PR5 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.